1 / 7

CARDS: The Collaborative Atorvastatin Diabetes Study

. . CARDS: The Collaborative Atorvastatin Diabetes Study - TRIAL DESIGN -. DesignMulticenter, multinational, randomized, double-blind, parallel groupPatients2838 patients aged 40-75 yrs with type 2 diabetes mellitus and at least one of: hypertension, retinopathy, albuminuria, smoking. Patients with history of MI, angina, coronary vascular surgery, cerebrovascular accident or severe peripheral vascular disease ineligibleFollow up and primary endpointPrimary endpoint: acute corona9449

daniel_millan
Download Presentation

CARDS: The Collaborative Atorvastatin Diabetes Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. CARDS: The Collaborative Atorvastatin Diabetes Study Purpose To assess the effectiveness of 10 mg atorvastatin daily in the primary prevention of cardiovascular disease in patients with type 2 diabetes, but without high concentrations of LDL-cholesterol Reference Colhoun HM, Betteridge PN, Hitman GA et al. Primary prevention of cardiovascular disease with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;264:685–696.

    2. CARDS: The Collaborative Atorvastatin Diabetes Study - TRIAL DESIGN - Design Multicenter, multinational, randomized, double-blind, parallel group Patients 2838 patients aged 40-75 yrs with type 2 diabetes mellitus and at least one of: hypertension, retinopathy, albuminuria, smoking. Patients with history of MI, angina, coronary vascular surgery, cerebrovascular accident or severe peripheral vascular disease ineligible Follow up and primary endpoint Primary endpoint: acute coronary event, coronary revascularization, or stroke. Median 3.9 years follow-up Treatment Atorvastatin 10 mg per day or placebo

    3. CARDS: The Collaborative Atorvastatin Diabetes Study - TRIAL DESIGN continued-

    4. CARDS: The Collaborative Atorvastatin Diabetes Study - RESULTS - Compared with placebo, patients receiving 10 mg atorvastatin daily showed a 37% reduction in major cardiovascular events from 9.0% to 5.8 % (p = 0.001) There was a favourable trend in the atorvastatin group with regard to all cause mortality, acute coronary events, coronary revascularization, and stroke Adverse event rate similar in atorvastatin and placebo groups. No cases of rhabdomyolysis.

    5. CARDS: The Collaborative Atorvastatin Diabetes Study - RESULTS continued -

    6. CARDS: The Collaborative Atorvastatin Diabetes Study - RESULTS continued -

    7. CARDS: The Collaborative Atorvastatin Diabetes Study - RESULTS continued -

    8. CARDS: The Collaborative Atorvastatin Diabetes Study - SUMMARY - Atorvastatin (10 mg, once daily) is safe and effective in reducing the risk of cardiovascular events, including stroke, in patients with type 2 diabetes There was a favourable trend in the atorvastatin group with regard to all cause mortality, major coronary events, coronary revascularization, and stroke

More Related